Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Goldman Sachs Healthcare Conference

ROCKVILLE, Md.--(BUSINESS WIRE)-- Human Genome Sciences, Inc. (NASDAQ:HGSI) announced today that its presentation at the Goldman Sachs 31st Annual Global Healthcare Conference will be webcast and may be accessed at www.hgsi.com.

A member of Human Genome Sciences’ senior management team will present a corporate overview on Tuesday, June 15, 2010, at 11:00 AM Eastern. Investors interested in listening to the live webcast should log on before the start time in order to download any software required. The archive of the webcast will be available for several days after the live event.

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs. The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax and cancer.

HGS and Human Genome Sciences are trademarks of Human Genome Sciences, Inc. For additional information on Human Genome Sciences, Inc., visit the company’s web site at www.hgsi.com.



CONTACT:

Human Genome Sciences, Inc.
Media Contact:
Jerry Parrott
Vice President, Corporate Communications
301-315-2777
or
Investor Contact:
Peter Vozzo
Senior Director, Investor Relations
301-251-6003

KEYWORDS:   United States  North America  Maryland

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Genetics  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.